Ncardia - About the company
Ncardia is a series C company based in The Hague (Netherlands), founded in 2011 by Stefan Braam. It operates as a Company offering hiPSC based products and services for drug discovery and development. Ncardia has raised $77.4M in funding from investors like Vesalius Biocapital Partners, Epimede and Kiniciti. The company has 88 active competitors, including 28 funded and 2 that have exited. Its top competitors include companies like Pandorum, InSphero and Newcells Biotech.
Company Details
Ncardia, formed by the merger of Pluriomics and Axiogenesis in 2017, is a stem-cell based drug discovery and development services provider specializing in offering hiPSC (human induced Pluripotent Stem Cells) based products and services. Both the companies were providers of human cardiovascular stem cell technology, disease modeling and cell-based assay products and services for cardiovascular drug development at the time of the merger. The company also offers its services for cardiovascular and neural safety and efficacy studies. The company has offices in Belgium, the Netherlands, Germany, and the USA. Their product portfolio includes cardiac cells (hiPSC-derived), cardiac fibroblasts, neural cells (includes pan-neuronal cells, astrocytes and peripheral neurons) and cardiac plates (ready-to-use assay plates).
- Website
- www.ncardia.com/
- Email ID
- *****@ncardia.com
- Registered Address
- Rue Edouard Belin 2 1435 Mont-Saint-Guibert
Key Metrics
Founded Year
2011
Location
The Hague, Netherlands
Stage
Series C
Total Funding
$77.4M in 6 rounds
Latest Funding Round
Investors
Ranked
3rd among 88 active competitors
Employee Count
42 as on Aug 31, 2026
Legal entities associated with Ncardia
Ncardia is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Ncardia Holding CIN: 0565.979.162 , Belgium, Active | Oct 28, 2014 | - | - | - |
Sign up to download Ncardia's company profile
Ncardia's funding and investors
Ncardia has raised a total funding of $77.4M over 6 rounds. Its first funding round was on Oct 24, 2014. Its latest funding round was a Series C round on Nov 16, 2021 for $*****. 1 investor participated in its latest round. Ncardia has 11 institutional investors.
Here is the list of recent funding rounds of Ncardia:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 16, 2021 | 4803555 | Series C | 1017591 | 7854760 | 7659004 | 1256965 |
Feb 01, 2020 | 2264335 | Grant (prize money) | 7460847 | 5744030 | 2280961 | |
Jan 01, 2020 | 1938543 | Grant (prize money) | 6143494 | 8190906 | 6215364 |
View details of Ncardia's funding rounds and investors
Ncardia's founders and board of directors
Founder? Claim ProfileThe founders of Ncardia is Stefan Braam.
Here are the details of Ncardia's key team members:
- Stefan Braam: Co-Founder & President of Ncardia. Contact Info: 1 email address
- Gustavo Mahler: CEO of Ncardia. They serve on the board of 1 company.Contact Info: 1 email address
View details of Ncardia's Founder profiles and Board Members
Ncardia's employee count trend
Ncardia has 42 employees as of Aug 26. Here is Ncardia's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ncardia's Competitors and alternates
Top competitors of Ncardia include Pandorum, InSphero and Newcells Biotech. Here is the list of Top 10 competitors of Ncardia, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of regenerative medicine and 3D tissues | $52.1M | 65/100 | ||
2nd | InSphero 2009, Schlieren (Switzerland), Series D | Developer of cell based assays for drug screening | $35M | 62/100 | |
3rd | Ncardia 2011, The Hague (Netherlands), Series C | Company offering hiPSC based products and services for drug discovery and development | $77.4M | 61/100 | |
4th | Newcells Biotech 2014, Newcastle Upon Tyne (United Kingdom), Series B | Developer of induced pluripotent stem cells derived organoid models for research application | $14.4M | 59/100 | |
5th | Parallel Bio 2020, Cambridge (United States), Series A | Limited information available | $25.4M | 54/100 | |
6th | Developer of stem-cell derived organoid models for cardiac drug discovery | $6.58M | 53/100 | ||
7th | ![]() Nextandbio 2019, Seoul (South Korea), Series A | Provider of organoid technology to develop customized treatments for patients | $5.27M | 48/100 | |
8th | BioDimension 2021, Bengaluru (India), Seed | Developer of biofabricating human tissues and organoids to make research | $983K | 44/100 | |
9th | SUN bioscience 2015, Lausanne (Switzerland), Funding Raised | Provider of 3D cell culture systems for personalized medicine and organoid research | - | 44/100 | |
10th | NEXEL 2012, Seoul (South Korea), Series B | Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids | $27M | 42/100 |
Looking for more details on Ncardia's competitors? Click here to see the top ones
Ncardia's Investments and acquisitions
Ncardia has made no investments or acquisitions yet.
Reports related to Ncardia
Here is the latest report on Ncardia's sector:
News related to Ncardia
•
Ncardia Launches iPSC-Derived Non-Human Primate Cardiomyocytes for Cardiac Safety ResearchBusiness Wire•Sep 23, 2025•Ncardia
•
Ncardia lanceert Ncyte® Microglia om onderzoek naar neurodegeneratieve ziekten te bevorderenBusiness Wire•Jan 27, 2025•Ncardia
•
Ncardia Launches Ncyte® Heart in a Box to Advance Cardiovascular Research and Precision MedicineBusiness Wire•Jan 27, 2025•Ncardia
•
Ncardia Launches Ncyte® Microglia to Advance Research in Neurodegenerative DiseasesBusiness Wire•Jan 27, 2025•Ncardia
•
Ncardia launches a series of ready-made tests to streamline the screening and selection of new therapeutic candidatesBusiness Wire•Sep 11, 2024•Ncardia
•
Ncardia Launches Panel of Ready-to-Use Assays to Streamline Screening and Selection of New Therapeutic CandidatesBusiness Wire•Sep 10, 2024•Ncardia
•
Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growthBusiness Wire•Jan 05, 2023•Ncardia, Cellistic, Dynamk Capital
•
•
•
Are you a Founder ?
FAQs about Ncardia
Explore our recently published companies
- Healthier You - India based, Unfunded company
- Newsdakiya - India based, Unfunded company
- 360 Photography - India based, Unfunded company
- MK Fanmade - India based, 2026 founded, Unfunded company
- India Pol Khol - India based, Unfunded company
- Hindi Link - India based, Unfunded company
